A common flu virus could be used to overcome patients’ resistance to certain cancer drugs — and improve how those drugs kill cancer cells, according to new research from Queen Mary University of London (QMUL).
The work, funded by UK charity Pancreatic Cancer Research Fund, contributes to a growing area in cancer treatment in which viruses are harnessed to kill cancer cells.
Viruses can be modified to specifically infect cancer cells, and use them as a factory to generate thousands of new viruses, replicating until the cancer cell bursts. The virus copies will then spread and infect surrounding tumour cells and repeat the process, leaving healthy cells unharmed.
But the body’s immune system will usually kill off the virus before it is able to infect all the cells within a tumour. In pancreatic cancer, therefore, drugs such as gemcitabine are currently the most common treatment — they work by damaging the DNA in the cancer cells, so they are unable to divide successfully. This damage triggers a process called apoptosis, in which damaged or unhealthy cells are forced to self-destruct.
Over time, however, the cancer cell becomes able to delay apoptosis in order to repair the damage to its DNA, which means that the cells survive and continue to divide and spread and the drug becomes less effective.
In a study published in the journal Oncotarget, the team at QMUL’s Barts Cancer Institute introduced a genetic modification to the virus, called adenovirus, to give it an extra weapon against cancer cells.
By switching off a particular gene in the virus which counteracts apoptosis, the scientists found cancer cells studied in the laboratory were unable to delay apoptosis and so forced to die without dividing. The modified virus still infects some cancer cells and replicates until the cell bursts, but by also preventing the cancer cells from developing drug resistance, it works with the anti-cancer drug to increase the number of cells that are killed.
“Many cancers — including pancreatic cancer — become resistant to treatments like gemcitabine, and currently there’s no way to get round that,” explains Dr Gunnel Halldèn, who led the research. “The virus that we have modified re-sensitises the resistant cancer cell by preventing the cell from repairing itself. The virus alone will kill some tumour cells, but in combination with the drug, the number of cells that are killed is greatly increased.
“Because the virus improves the efficacy of the drug, it means it could also be possible to give lower doses, which will also reduce the unpleasant side-effects associated with chemotherapy,” she adds.
Developing virus-based cancer therapies has been a key goal in cancer research for several years and some technologies have already moved into the clinic: last year, for example, a melanoma therapy, based on a herpes virus called T-VEC, was approved for use in the US and in Europe.
The QMUL research is at an early stage, but the team believe they have found a promising new route for developing combination treatments for pancreatic cancer.
The next step for the researchers will be to test other modified versions of adenovirus to better understand the exact mechanism through which it enhances cell killing. Further modifications will also be made to enable the virus to trigger the body’s immune system, which will attack any cancer cells that have not been infected by the virus.
The Latest on: Virus-based cancer therapies
via Google News
The Latest on: Virus-based cancer therapies
- The Good that Viruses Doon May 10, 2022 at 6:57 am
Advances in microscopy later revealed what phages really are: viruses that infect bacteria and single-celled microbes known as archaea while ignoring plants and animals. Endeavors like d’Hérelle’s ...
- Prostate cancer: New magnet therapy could improve treatment for the deadly diseaseon May 9, 2022 at 6:57 am
This may include adverts from us and 3rd parties based on ... the moment the treatment only works on prostate and breast cancer, the most prevalent cancer among women, but the team wants to expand the ...
- SCG Cell Therapy announces HSA clinical trial approval of TCR-T cell therapy for liver canceron May 8, 2022 at 9:05 pm
SCG101 is being developed to treat hepatitis B virus (HBV) related hepatocellular carcinoma ... providing patients with access to evidence-based cancer diagnostics, technology and therapies. For more ...
- New method can easily identify viruses in tumors in a routine clinical genomic sequencing assayon May 6, 2022 at 2:33 am
Researchers have developed a method to accurately detect viruses from clinical next-generation sequencing and describe novel associations between specific tumors and viruses that warrant further ...
- He got throat cancer even though he was never a smoker. The cause? An HPV infectionon May 5, 2022 at 2:23 pm
A complex combination of genetics, environment and virus-host dynamics could play a role in the development of long-term diseases.
- Former cancer patients not more likely to die from COVIDon May 5, 2022 at 3:57 am
A study finds that former cancer patients are not more likely to die from COVID than non-cancer patients, if they aren't in active treatment ...
- Exploring oncolytic viral therapeutics and immunotherapies derived from DNA and RNAon April 28, 2022 at 5:53 am
Second, the growing data on cancer-based immunotherapies was described ... vectors with specified features are used in oncolytic virus therapy to only attack and destroy cancerous cells as ...
- Oncolytic Virus Therapies Market Emerging Trend, Analysis & Competition Tracking – Global Market Insights 2021 to 2028on April 15, 2022 at 4:49 am
Oncolytic virus therapies has emerged as a relevant tool to target different kinds of cancer such as breast cancer ... Chapters 5 includes market segmentation based on product type, application ...
- Fighting Cancer with a Trojan Horseon April 12, 2022 at 9:00 am
“The unprotected oncolytic viruses used in the past were quickly ... at distant metastatic tumor sites.” Creating cell-based cancer therapies always comes with challenges in bioprocessing.
- Cancer-fighting viruses soften up their victims before attackingon April 11, 2022 at 8:01 am
"Cancer cells are constantly evolving ... are transformative for the fields of oncolytic viruses, miRNA therapeutics and exosome-based therapies." The researchers note that while many groups ...
via Bing News